Elzbieta M. van der Steen‐Banasik

Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts

Ellen Stelloo, Remi A. Nout, Elisabeth M. Osse et al. · Clinical Cancer Research · 2016 · 858 citations

Medicine, Gynecology, Oncology +17

Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer – A pooled analysis of PORTEC 1 and 2 trials

Tjalling Bosse, Elke E.M. Peters, Carien L. Creutzberg et al. · European Journal of Cancer · 2015 · 430 citations · Full text

Medicine, Gynecology, Oncology +9

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy

Bastiaan G. Wortman, Carien L. Creutzberg, Hein Putter et al. · British Journal of Cancer · 2018 · 282 citations · Full text

Medicine, Oncology, Radiation Oncology +15

Quality of Life After Pelvic Radiotherapy or Vaginal Brachytherapy for Endometrial Cancer: First Results of the Randomized PORTEC-2 Trial

Remi A. Nout, Hein Putter, Ina M. Jürgenliemk‐Schulz et al. · Journal of Clinical Oncology · 2009 · 272 citations

Medicine, Oncology, Radiation Oncology +16

PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer

Anne Sophie V M van den Heerik, Nanda Horeweg, Remi A. Nout et al. · International Journal of Gynecological Cancer · 2020 · 248 citations · Full text

Medicine, Gynecology, Oncology +17